Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.43 USD | +6.28% | +17.77% | +337.41% |
Apr. 11 | Sector Update: Health Care Stocks Decline Thursday Afternoon | MT |
Apr. 11 | Candel Therapeutics Shares Rise After FDA Orphan Drug Designation for Potential Pancreatic Cancer Drug | MT |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 189M |
---|---|---|---|---|---|
Net income 2024 * | -41M | Net income 2025 * | - | EV / Sales 2024 * | - |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-7.07
x | P/E ratio 2025 * |
-
| Employees | 42 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 65.01% |
1 day | +6.28% | ||
1 week | +17.77% | ||
Current month | +306.96% | ||
1 month | +323.03% | ||
3 months | +410.32% | ||
6 months | +622.47% | ||
Current year | +337.41% |
Managers | Title | Age | Since |
---|---|---|---|
Paul-Peter Tak
CEO | Chief Executive Officer | 64 | 20-08-31 |
Founder | 66 | 01-12-31 | |
Charles Schoch
DFI | Director of Finance/CFO | 39 | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Joseph Papa
BRD | Director/Board Member | 68 | 22-08-07 |
Edward Benz
BRD | Director/Board Member | 78 | 17-08-31 |
Paul Manning
CHM | Chairman | 68 | 18-10-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-25 | 6.43 | +6.28% | 750,648 |
24-04-24 | 6.05 | +2.37% | 672,175 |
24-04-23 | 5.91 | +6.68% | 462,336 |
24-04-22 | 5.54 | +7.16% | 581,998 |
24-04-19 | 5.17 | -5.31% | 568,360 |
Delayed Quote Nasdaq, April 25, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+337.41% | 189M | |
+1.12% | 42.59B | |
+6.77% | 40.65B | |
+45.26% | 40.57B | |
-11.96% | 26.77B | |
+6.01% | 24.81B | |
-24.92% | 18.17B | |
-3.63% | 11.7B | |
+27.16% | 12.05B | |
+7.30% | 11.1B |
- Stock Market
- Equities
- CADL Stock